Blood-based biomarkers for Alzheimer’s disease: a multicenter-based cross-sectional and longitudinal study in China

• DOI: 10.1016/j.scib.2023.07.009
• Publication Date: 2023-07-11T01:14:11Z
• Authors: Feng Gao; Linbin Dai; Qiong Wang; Chang Liu; Kexue Deng; Zhaozhao Cheng; Xinyi Lv; Yan Wu; Ziyi Zhang; Qingqing Tao; Jing Yuan; Shiping Li; Yue Wang; Ya Su; Xin Cheng; Jun Ni; Zhiying Wu; Shuting Zhang; Jiong Shi; Yong Shen
• Keywords: Apolipoprotein E; Amyloid beta

Discrepancies in diagnostic biomarkers for Alzheimer's Disease (AD) may arise from racial disparities, risk factors, or lifestyle differences. Moreover, there has been a lack of systematic and multicenter studies to evaluate baselines the AD Chinese populations. Thus, is an urgent need research investigate effectiveness blood AD, specifically Han population, using approach. In present multicenter-based cross-sectional longitudinal study, we evaluated 817 samples 6 different clinical centers. We measured plasma amyloid beta (Aβ)-40, Aβ42, phosphorylated tau 181 (pTau), total (tTau), serum neurofilament light (NFL), glial fibrillary acidic protein (GFAP). Additionally, 18F-florbetapir positron electron tomography magnetic resonance imaging were also performed. A combination APOE genotype with pTau GFAP demonstrated exceptional performance distinguishing Aβ status. Furthermore, baseline levels exhibited strong association cognitive decline over time brain atrophy, higher predicting faster rate neurodegeneration. summary, these results validate practicality encompassing various regions within China. they emphasize potential as non-invasive methods detecting screening at early stage.